Onasemnogene Abeparvovec-brve
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy
Trial Timeline
Jul 1, 2026 → Jun 30, 2032
NCT ID
NCT07448610About Onasemnogene Abeparvovec-brve
Onasemnogene Abeparvovec-brve is a approved stage product being developed by Novartis for Spinal Muscular Atrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07448610. Target conditions include Spinal Muscular Atrophy.
What happened to similar drugs?
6 of 20 similar drugs in Spinal Muscular Atrophy were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07448610 | Approved | Recruiting |
Competing Products
20 competing products in Spinal Muscular Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 35 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 42 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 36 |
| Elezanumab | AbbVie | Pre-clinical | 30 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 40 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 21 |
| Zolgensma | Novartis | Pre-clinical | 33 |
| BVS857 + Placebo | Novartis | Phase 2 | 35 |
| AVXS-101 | Novartis | Phase 1 | 29 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 44 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 30 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| branaplam | Novartis | Phase 1/2 | 32 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 47 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 40 |
| Risdiplam | Roche | Phase 1 | 29 |
| ATI355 | Novartis | Phase 1 | 29 |